Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.
Daniel J KraussTheodore KarrisonAlvaro A MartinezGerard C MortonDi YanDeborah Watkins BrunerBenjamin MovsasMohamed ElshaikhDeborah E CitrinBruce HershatterJeff M MichalskiJason Alexander EfstathiouAdam CurreyVivek S KavadiFabio L CuryMichael LockAdam RabenSamantha Andrews SeawardAli El-GayedJoseph P RodgersHoward M SandlerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
STAD did not improve OS rates for men with IRPC treated with dose-escalated RT. Improvements in metastases rates, prostate cancer deaths, and PSA failures should be weighed against the risk of adverse events and the impact of STAD on quality of life.